by Dr. Walter I. Sussman

Shoulder pain following vaccination has become an increasingly recognized medical and legal issue over the past decade. The condition known as Shoulder Injury Related to Vaccine Administration (SIRVA) is now included within the National Vaccine Injury Compensation Program (VICP) and has generated thousands of claims. However, one of the greatest challenges facing physicians, attorneys, and patients is determining whether shoulder symptoms truly represent SIRVA or simply reflect previously existing degenerative shoulder disease that became symptomatic around the time of vaccination.

This distinction is critical. While SIRVA is considered an injury resulting from improper vaccine administration, degenerative shoulder conditions are extremely common in the general population and often exist long before symptoms develop. Understanding the differences can help guide diagnosis, treatment, and medico-legal evaluation.

What Is SIRVA?

SIRVA refers to shoulder pain and dysfunction that occurs following vaccine administration, typically due to improper injection technique. Rather than being injected into the deltoid muscle, the vaccine may be delivered too high or too deep, resulting in inflammation of structures such as the subacromial bursa, rotator cuff tendons, joint capsule, or surrounding tissues (MacMahon et al, 2022; Miller et al, 2026).

It is notably described as a "medicolegal term rather than a true diagnosis." The AAOS review emphasizes that it was introduced in 2010 by the Vaccine Injury Compensation Program (VICP) after an increase in claims (Wiesel & Keeling, 2021). The 2024 National Academies of Science, Engineering, and Medicine (NASEM) review further clarified that SIRVA "represents a clinical syndrome, is not a specific diagnosis, and may have a number of causes."

The National Vaccine Injury Compensation Program generally recognizes several hallmark features:

• Shoulder pain beginning within 48 hours of vaccination: Multiple studies confirm that symptoms most commonly begin within 48 hours of vaccination. However, Fortier et al. (2024) found that in COVID-19 SIRVA cases, symptoms occurred most commonly after at least 72 hours (30.9%), suggesting some variability (Fortier et a, 2024; Martín Arias et al, 2017; Janssen et al, 2023; Wiesel & Keeling, 2021).
• Symptoms localized to the vaccinated shoulder: Pain (97.7%) and limited range of motion (68.1%) localized to the injected shoulder are the most commonly reported symptoms (Bass and Poland, 2022).
• No prior history of pain, dysfunction, or treatment involving that shoulder: This is a VICP criterion, though it is worth noting that Slette et al. (2022) raised an important counterpoint, persistent shoulder pain after vaccination frequently overlaps with common incidental pathology (rotator cuff tendinopathy, adhesive capsulitis), establishing "a high probability of a coincidental rather than a causal association" in many cases (Slette et al, 2022).
• Persistent symptoms extending beyond the expected soreness associated with routine vaccination: SIRVA is distinguished from typical post-vaccination soreness by its severity and duration. In the Bass & Poland (2022) VAERS review, only 5 of 65 patients with follow-up data reported recovery, while 60 had not yet recovered, and 23.3% reported disability. (Bass and Poland, 2022).

Unlike routine post-vaccination soreness, SIRVA often results in significant pain, loss of range of motion, weakness, and functional limitations that may persist for months or years.

How Common is SIRVA?

The incidence appears rare but likely underreported. MacMahon et al. estimated approximately 1 in 130,000 vaccination events based on the best available comparative study (MacMahon et al, 2022).

However, Janssen et al. (2023) found a much higher prevalence of 3.3% among Dutch hospital workers after COVID-19 vaccination when actively surveyed, with 56.2% of affected individuals still symptomatic at follow-up (Janssen et al, 2023). The CDC's Vaccine Safety Datalink estimated 7.78 additional cases of bursitis per million people vaccinated (Miller et al, 2026).

Why the Diagnosis Is Challenging

The difficulty arises because degenerative shoulder disease is extraordinarily common.

Numerous imaging studies have demonstrated that asymptomatic abnormalities are frequently present in individuals with no shoulder complaints. Rotator cuff tears, bursitis, tendinosis, labral degeneration, and arthritis become increasingly prevalent with age.

Prevalence of Rotator Cuff Pathology in Asymptomatic Shoulders

Research has shown that more than 50% of individuals over age 65 may have a rotator cuff tear visible on imaging, many without symptoms. The presence of these findings after vaccination does not necessarily prove that the vaccine caused the pathology.

• The AAOS Clinical Practice Guideline on Management of Rotator Cuff Injuries reported that 54% of asymptomatic patients aged 60 years and greater have sustained either a partial or complete rotator cuff tear on MRI (Brown et a, 2025).
• Ultrasound studies cited in the same guideline show 13% prevalence in the fifth decade, 20% in the sixth decade, and 31% in the seventh decade (Brown et a, 2025).
• The Ibounig et al. data further corroborate this, with partial- and full-thickness tears combined exceeding 90% prevalence in the oldest age groups studied (Ibounig et al, 2026).
• A systematic review of 53 studies (Sanders et al., 2025) found that the prevalence of rotator cuff imaging abnormalities in asymptomatic shoulders ranged widely with full-thickness tears found in 11–17% of population-based ultrasound samples and up to 20% on MRI, while tendinopathy and/or partial-thickness tears reached 34–65% in population-based samples (Sanders et al, 2025).

Beyond the Rotator Cuff: Glenohumeral Joint Pathology

The SCRUTINY systematic review (Ibounig et al., 2024) found that the population-based prevalence of glenohumeral joint imaging abnormalities in asymptomatic individuals may range between 30% and 75%,including glenohumeral osteoarthritis (15–75%), labral abnormalities (20%), and long head of biceps tendon abnormalities (30%) (Ibounig et al, 2024).

The Diagnostic Dilemma: New Injury vs. Unmasked Pathology

• Sette et al. (2022) conducted a systematic review of 28 published SIRVA case reports and found that the most common specific diagnoses were rotator cuff tendinopathy (9/16) and adhesive capsulitis (4/16), both exceedingly common age-related conditions. They concluded that persistent shoulder pain after vaccination "overlaps with common shoulder pathology" and that this "establishes a high probability of a coincidental rather than a causal association." (Slette et al, 2022)
• The Ibounig et al. (2026) study provides the strongest quantitative framework for understanding this dilemma. The authors note that in middle-aged and older adults, the pretest probability of MRI-detected rotator cuff changes approaches 100%, which means "the mere presence of an abnormality has limited diagnostic value." They argue that a positive MRI result "does not confirm causality unless features such as a clear traumatic event, acute strength loss, or persistent functional deficit increase the pretest probability." (Ibounig et al, 2026)
• Conversely, the NASEM (2024) review did find a causal relationship between vaccine administration and specific diagnoses, subacromial/subdeltoid bursitis, acute rotator cuff or biceps tendinopathy, bone injury, and nerve injury, stating "these injuries are due to injection into the tissue resulting in the damage." (Miller et al, 2026)
• MacMahon et al. (2022) estimated the incidence at approximately 1 in 130,000 vaccination events, suggesting that while rare, true vaccine-induced shoulder injury does occur (MacMahon et al, 2022).

The tension between these perspectives has direct clinical relevance. As Ibounig et al. recommend, clinicians should shift from asking "whether abnormalities exist" to "whether they plausibly explain the clinical findings," and consider adopting "more precise and less value-laden terminology," such as "structural alteration" or "degeneration" rather than "tear," to reduce overdiagnosis and unnecessary intervention (Ibounig et al, 2026).

Wright et al. (2023) further note that advanced imaging in SIRVA cases "rarely provided information that affected treatment," reinforcing the limited utility of imaging in this context (Wright et al, 2023).

Key Historical Features That Support SIRVA

1. Timing of Symptom Onset

One of the strongest indicators of SIRVA is the rapid onset of symptoms, and the VICP's Vaccine Injury Table specifies onset within 48 hours as a criterion for SIRVA claims (MacMahon et al, 2022; Wiesel & Keeling, 2021).

Most reported cases develop pain immediately or within 24 to 48 hours following vaccination. Some patients describe severe pain beginning during the injection itself.

In contrast, degenerative shoulder disease typically develops gradually over weeks, months, or years.

2. Absence of Prior Symptoms

Perhaps the most important criterion involves the patient's pre-vaccination shoulder status. The VICP criteria explicitly require no prior history of pain or dysfunction in the affected shoulder (Wright et al, 2023; Wiesel & Keeling, 2021).

Wright et al. (2023) confirmed in their systematic review that the absence of prior shoulder complaints is a key diagnostic feature, noting that SIRVA is defined partly by "no history of pain, inflammation, or dysfunction of the affected shoulder prior to vaccination" (Wright et al, 2023).

Questions to consider include:

• Did the patient have prior shoulder pain?
• Was there previous treatment?
• Any prior physical therapy?
• Prior injections?
• Previous imaging studies?
• History of overhead sports or occupations?

The stronger the evidence that the shoulder was asymptomatic before vaccination, the stronger the argument for SIRVA.

3. Localization to the Vaccinated Shoulder

True SIRVA symptoms occur in the same shoulder that received the vaccine.

Patients often describe:

• Lateral shoulder pain
• Pain with overhead activity
• Difficulty sleeping on the affected side
• Loss of range of motion
• Weakness

The symptoms are generally unilateral and directly correspond to the injection site.

Imaging Findings are Helpful but Not Diagnostic

MRI and ultrasound frequently identify abnormalities in patients suspected of having SIRVA, but imaging alone cannot establish causation.

Common imaging findings include:

• Subacromial-subdeltoid bursitis
• Rotator cuff tendinopathy
• Partial-thickness rotator cuff tears
• Synovitis
• Adhesive capsulitis
• Joint effusions
• Bone marrow edema

The problem is that many of these findings are also common in degenerative shoulder disease.

• Donners et al. (2023) found in a case series of 9 chronic SIRVA patients that the most common MRI findings were greater tuberosity erosions (89%), infraspinatus tendonitis (78%), capsulitis (56%), synovitis (56%), and bone marrow edema (56%). Notably, greater tuberosity erosions may be a more specific finding for SIRVA, as they are less commonly seen in typical degenerative disease (Donners et al, 2023).

• Fortier et al. (2024) found that across 81 COVID-19 SIRVA cases, the most common diagnoses were bursitis (32.1%), adhesive capsulitis (27.2%), and rotator cuff tear or tendinopathy (21.0%) (Fortier et a, 2024).

• Wright et al. (2023) importantly noted that advanced imaging in SIRVA cases "rarely provided information that affected treatment", reinforcing the limited utility of imaging for establishing causation (Wright et al, 2023).

For example, a 65-year-old patient with a rotator cuff tear on MRI may have had that tear for years before vaccination. The MRI cannot determine whether the tear was caused by the injection or merely discovered after symptoms developed.

Imaging cannot determine whether pathology was caused by the injection
or merely discovered afterward, and is the crux of the ongoing debate in
the literature, which is why imaging findings must always be interpreted alongside the clinical history.

The Role of Degenerative Shoulder Disease

Current evidence suggests that many patients who develop SIRVA symptoms may have underlying degenerative pathology that was previously asymptomatic.

Rather than creating a brand-new rotator cuff tear, the vaccine-related inflammatory response may aggravate pre-existing disease.

This concept is particularly important because:

• Degenerative pathology is common
• Many abnormalities remain asymptomatic
• Local inflammation may convert a silent condition into a painful one

The medical question often becomes whether vaccination caused a new injury or exacerbated an existing condition.

The proposed pathophysiology supports this concept: SIRVA is hypothesized to involve an immune-mediated inflammatory response to vaccine antigens injected into or near the subacromial bursa or synovium (Miller et al, 2026; Yuen et al, 2022). This local inflammatory cascade could plausibly irritate preexisting degenerative tissue that was previously quiescent.

What the National Academies Have Concluded

The National Academies of Sciences, Engineering, and Medicine reviewed available evidence regarding vaccine administration injuries and concluded that improperly administered vaccines can produce local inflammatory reactions involving shoulder structures (Miller et al, 2026).

The NASEM review found a causal relationship between
vaccine administration and four specific diagnoses:

1. subacromial/subdeltoid bursitis
2. acute rotator cuff or acute biceps tendinopathy
3. bone injury
4. axillary or radial nerve injury

The report states that "these injuries are due to injection into the tissue resulting in the damage." Importantly, the NASEM also clarified that SIRVA "represents a clinical syndrome, is not a specific diagnosis, and may have a number of causes."

However, the report also acknowledged significant limitations in proving direct causation for many specific imaging findings. The available evidence supports an association between improper vaccine placement and shoulder injury, but distinguishing vaccine-induced pathology from naturally occurring degenerative disease remains challenging in many cases.

Physical Examination Clues

Several examination findings may help differentiate SIRVA from chronic degenerative disease.

Patients with SIRVA often demonstrate significant pain with shoulder motion, marked reduction in active range of motion, painful arc, and diffuse tenderness around the injection region are consistently documented.

• Bass & Poland (2022) found that 97.7% of SIRVA patients reported pain and 68.1% reported limited range of motion as their primary symptoms (Bass and Poland, 2022).
• MacMahon et al. (2022) confirmed that the most common clinical features
  were shoulder pain and reduced ROM across all case reports and database
  studies (MacMahon et al, 2022).
• Petrakis et al. (2023) similarly found that most patients experienced
  shoulder pain and restricted movement within 24 hours of vaccination in
  their cohort of 151 confirmed SIRVA cases (Petrakis et a, 2023).

Adhesive capsulitis-like stiffness is particularly common in some patients with SIRVA.

• Bass & Poland (2022) found adhesive capsulitis and bursitis to be
  the most common imaging-confirmed diagnoses among 95 patients (Bass and Poland, 2022).
• Fortier et al. (2024) reported adhesive capsulitis in 27.2% of 81 COVID-19 SIRVA cases (Fortier et a, 2024).
• Ghosh et al. (2023) described a case series of 9 patients who developed
  adhesive capsulitis within one month of COVID-19 vaccination,
  fulfilling the UK FROST Multicenter Study diagnostic criteria, with a
  mean symptom onset of 12.3 days post-vaccination (Ghosh et al, 2023).

Conversely, longstanding degenerative disease may demonstrate:

• Chronic weakness patterns
• Muscle atrophy
• Long-standing motion limitations
• Bilateral degenerative changes

The examination rarely provides a definitive answer but helps build the overall clinical picture.

Why Accurate Diagnosis Matters

Distinguishing SIRVA from pre-existing shoulder disease has implications beyond treatment.

The diagnosis may affect:

• Eligibility for VICP compensation: SIRVA was added to the Vaccine Injury Table in 2017, and the VICP defines it as symptom onset within 48 hours after vaccination, with pain and decreased range of motion in the vaccinated arm, and no other abnormalities or prior history that could explain the symptoms. Hesse et al. (2020) documented that VICP claims increased dramatically from 2 in 2011 to 227 in 2016, with SIRVA now accounting for approximately half of all claims to the VICP (Miller et al, 2026; Slette et al, 2022; Hesse et al, 2020).
• Medical causation opinions: Among conceded VICP claims, 71.9% of healthcare providers who gave opinions on causality considered the injury was caused by vaccination. However, Wiesel & Keeling (2021) emphasized that SIRVA is "a medicolegal term rather than a true diagnosis," highlighting the tension between clinical and legal frameworks (Wiesel & Keeling, 2021; Hesse et al, 2020).
• Disability determinations & Treatment recommendations: Among VICP-conceded claims, 80.0% received physical or occupational therapy, 60.1% had at least one steroid injection, and 32.6% underwent surgery. Only 24.3% had symptom resolution by the last available medical visit. Bass & Poland (2022) found that 23.3% of unrecovered patients reported disability (Bass and Poland, 2022; Hesse et al, 2020). Learn about minimally invasive treatment options here.

Practical Takeaway

SIRVA remains a diagnosis based primarily on clinical history rather than imaging findings. The physical examination findings described for both SIRVA and chronic degenerative disease are accurate and well-supported. The key
distinguishing features are temporal: SIRVA presents with acute-onset pain, diffuse tenderness, and inflammatory restriction of motion, while chronic degenerative disease demonstrates insidious weakness, muscle atrophy, fatty infiltration, and often bilateral involvement.

The strongest evidence supporting SIRVA includes:

• No prior symptomatic shoulder condition
• Pain beginning within 48 hours of vaccination
• Symptoms localized to the vaccinated shoulder
• Persistent dysfunction beyond expected vaccine soreness

Because degenerative shoulder abnormalities are common, MRI findings alone cannot distinguish SIRVA from pre-existing disease. Instead, diagnosis requires integration of timing, symptoms, prior medical history, physical examination, and imaging findings.

For patients, physicians, and attorneys alike, understanding this distinction is essential when evaluating whether a vaccine-related shoulder injury truly represents SIRVA or the unmasking of previously silent degenerative disease.

(781) 591-7855

info@BSBortho.com

20 Walnut St

Suite 14

Wellesley MA 02481

References

Bass JR, Poland GA. Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination. Vaccine. 2022 Aug 12;40(34):4964-4971. doi: 10.1016/j.vaccine.2022.06.002. Epub 2022 Jun 8. PMID: 35817645; PMCID: PMC9174179.

Brown GA, Weber S, Chahla J, et al. Management of Rotator Cuff Injuries: Evidence-Based Clinical Practice Guideline. American Academy of Orthopaedic Surgeons. 2025. https://www.aaos.org/rccpg2025

Donners R, Gehweiler J, Kovacs B, Breit HC, Daikeler T, Harder D, Berger CT. Chronic stage magnetic resonance imaging findings in patients with shoulder injury related to vaccine administration (SIRVA). Skeletal Radiol. 2023 Sep;52(9):1695-1701. doi: 10.1007/s00256-023-04334-3. Epub 2023 Apr 3. PMID: 37012390; PMCID: PMC10069733.

Fortier LM, Smith KL, Ina JG, Sinkler MA, Calcei JG, Salata MJ, Gillespie R, Voos JE. Common characteristics of shoulder injury related to vaccine administration following COVID-19 vaccination: a comprehensive systematic review. J Shoulder Elbow Surg. 2024 Jan;33(1):202-209. doi: 10.1016/j.jse.2023.07.040. Epub 2023 Sep 3. PMID: 37660886.

Ghosh S, Pandey SK, Biswas A, Pandey J. Adhesive Capsulitis After COVID-19 Vaccination: A Case Series. Am J Phys Med Rehabil. 2023 Jun 1;102(6):e79-e82. doi: 10.1097/PHM.0000000000002194. Epub 2023 Jan 23. PMID: 36722847; PMCID: PMC10184708.

Hesse EM, Atanasoff S, Hibbs BF, Adegoke OJ, Ng C, Marquez P, Osborn M, Su JR, Moro PL, Shimabukuro T, Nair N. Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010-2016. Vaccine. 2020 Jan 29;38(5):1076-1083. doi: 10.1016/j.vaccine.2019.11.032. Epub 2019 Nov 23. PMID: 31771864; PMCID: PMC9169064.

Ibounig T, Järvinen TLN, Raatikainen S, Härkänen T, Sillanpää N, Bensch F, Haapamäki V, Toivonen P, Björkenheim R, Ryösä A, Kanto K, Lepola V, Joukainen A, Paavola M, Koskinen S, Rämö L, Buchbinder R, Taimela S. Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging. JAMA Intern Med. 2026 Apr 1;186(4):406-414. doi: 10.1001/jamainternmed.2025.7903. PMID: 41697693; PMCID: PMC12910452.]

Ibounig T, Sanders S, Haas R, Jones M, Järvinen TL, Taimela S, Docking S, Rämö L, Buchbinder R. Systematic Review of Shoulder Imaging Abnormalities in Asymptomatic Adult Shoulders (SCRUTINY): Abnormalities of the glenohumeral joint. Osteoarthritis Cartilage. 2024 Oct;32(10):1184-1196. doi: 10.1016/j.joca.2024.06.001. Epub 2024 Jun 12. PMID: 38876437.

Janssen ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO. The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers. Vaccine. 2023 Sep 22;41(41):6042-6047. doi: 10.1016/j.vaccine.2023.08.043. Epub 2023 Aug 25. PMID: 37635003.

MacMahon A, Nayar SK, Srikumaran U. What Do We Know About Shoulder Injury Related to Vaccine Administration? An Updated Systematic Review. Clin Orthop Relat Res. 2022 Jul 1;480(7):1241-1250. doi: 10.1097/CORR.0000000000002181. Epub 2022 Mar 24. PMID: 35323136; PMCID: PMC9191332.

Martín Arias LH, Sanz Fadrique R, Sáinz Gil M, Salgueiro-Vazquez ME. Risk of bursitis and other injuries and dysfunctions of the shoulder following vaccinations. Vaccine. 2017 Sep 5;35(37):4870-4876. doi: 10.1016/j.vaccine.2017.07.055. Epub 2017 Jul 31. PMID: 28774564.

Miller ER, Marquez P, Aynalem G, et al. Atypical Shoulder Pain and Dysfunction After Vaccinations Reported to the Vaccine Adverse Event Reporting System (VAERS) January 1, 2018, Through October 31, 2022. Pharmacoepidemiology and Drug Safety. Volume 35, Issue 6 e70397

Petrakis N, Addison M, Penak B, Schrader S, Mallard J, Clothier HJ, Buttery JP, Crawford NW, Cheng DR. Shoulder injury following COVID-19 vaccine administration: a case series and proposed diagnostic algorithm. Expert Rev Vaccines. 2023 Jan-Dec;22(1):299-306. doi:10.1080/14760584.2023.2189463. PMID: 36894495.

Sanders S, Ibounig T, Haas R, Jones M, Rämö L, Docking S, Järvinen T, Taimela S, Hoffmann T, Buchbinder R. Rotator Cuff Imaging Abnormalities in Asymptomatic Shoulders: A Systematic Review. J Orthop Sports Phys Ther. 2025 Dec;55(12):1-16. doi: 10.2519/jospt.2025.13611. PMID: 41308021.

Slette E, Rohrback M, Ring D. Persistent Shoulder Pain After Vaccine Administration Is Associated with Common Incidental Pathology: A Systematic Review. Clin Orthop Relat Res. 2022 Jul 1;480(7):1251-1258. doi: 10.1097/CORR.0000000000002191. Epub 2022 Mar 23. PMID: 35319515; PMCID: PMC9191317.

Wiesel BB, Keeling LE. Shoulder Injury Related to Vaccine Administration. J Am Acad Orthop Surg. 2021 Sep 1;29(17):732-739. doi: 10.5435/JAAOS-D-21-00021. PMID: 34185028.

Wright JO, Wiggins W, Smith MS, King JJ, Wright TW. Shoulder Pain and Dysfunction After Vaccination: A Systematic Review. JBJS Rev. 2023 Jan 12;11(1). doi: 10.2106/JBJS.RVW.22.00134. PMID: 36722836.

Yuen WLP, Loh SYJ, Wang DB. SIRVA (Shoulder Injury Related to Vaccine Administration) following mRNA COVID-19 Vaccination: Case discussion and literature review. Vaccine. 2022 Apr 20;40(18):2546-2550. doi: 10.1016/j.vaccine.2022.03.037. Epub 2022 Mar 21. PMID: 35339304; PMCID:
PMC8934720.